ctos®

2026 Annual Meeting

Coex Convention Center
Seoul, South Korea





November 18-21
2026

THANK YOU

The Connective Tissue Oncology Society
greatly appreciates your support of the 2026 Annual Meeting.

PLATINUM SPONSORS

ADI bioscience

cogent BIOSCIENCES

deciphera® a member of ONO PHARMA

GSK

INHIBRX

MERCK

Immunome®

SILVER SPONSORS

Parabilis MEDICINES

恒瑞

BRONZE SPONSORS

Pharma Mar

TEMPUS

SPECIAL THANKS TO FRIENDS OF CTOS

STORM THERAPEUTICS

2026 CTOS Welcome

We are delighted to present the 2026 CTOS Annual Meeting in Seoul, South Korea. This is the second time the Annual Meeting has been held in Asia and we welcome colleagues and friends from all over the world.

The CTOS Annual Meeting will continue to foster collaboration and advance our understanding of the biology of these complex cancers. Prior to the start of the meeting, The Science of Sarcomas Symposium will be held along with the TARPSWG, Ultra-Rare Sarcomas and SARC meetings. All registrants are welcome to attend these meetings.

The Sarcoma of the Year is rhabdomyosarcoma, a challenging disease spanning a wide age range and consequently requiring input from all specialities within the clinical multi-disciplinary team as well laboratory researchers. Other highlights of the program include the Herman Suit Lecture delivered by Dr. Elizabeth Baldini and the Nina Axelrad Lecture given by Dr. William Tap. CTOS will continue to support the development of the next generation of sarcoma clinicians and researchers with the interactive Mentorship Sessions on Friday morning.

As always, networking is a key highlight of CTOS. Attendees will have ample opportunities to connect with colleagues during breakfast, lunches, receptions and of course at the Gala (and after party) on Friday night. This year, we are also excited to introduce “CTOS Got Talent”, which will contribute to an engaging and collaborative experience for everyone!

See you in Seoul!

Sincerely yours,
Robin Jones, MD, 2026 CTOS President

2026 Program Committee
Aisha Miah, MBBS, MRCP, FRCR, PhD, Chair
Josephine Dermawan, MD, PhD
Ilkyu Han, MD, PhD
Joanna Szkandera, MD
Michiel van de Sande, MD, PhD

OGSIVEO as monotherapy is indicated for the treatment of adult patients with progressing desmoid tumours who require systemic treatment[1]



OGSIVEO has robust clinical and real-world experience with nearly 4500 patients in 28 countries treated worldwide and over 4 years of published, long-term data.[1–4]

OGSIVEO paved the way as the first and only desmoid tumour therapy approved for adults by the FDA, EMA, MHRA, and Swissmedic, and in the UAE[5–9]

Scan to see the OGSIVEO EMA-approved SmPC in English

Learn more about OGSIVEO by visiting **OGSIVEO.com/hcp**

EMA, European Medicines Agency; FDA, U.S. Food and Drug Administration; MHRA, Medicines and Healthcare products Regulatory Agency; UAE, United Arab Emirates.

References: 1. Ogsiveo® (nirogacestat) EU SmPC. Amsterdam, The Netherlands: Merck Europe B.V.; August 2026. **2.** Data on file. SpringWorks Therapeutics, Inc. **3.** Gounder M, Ratan R, Alcindor T, et al. Nirogacestat, a gamma-secretase inhibitor for desmoid tumours. *N Engl J Med.* 2023;388(10):898-912. **4.** Ratan R, Kasper B, Alcindor T, et al. Efficacy and safety of long-term continuous nirogacestat treatment in adults with desmoid tumours: Results from the DeFi trial. *J Clin Oncol.* 2025;43(34):3646-3651. **5.** US Food and Drug Administration. FDA approves nirogacestat for desmoid tumors. FDA News Release. November 27, 2023. Accessed September 1, 2026. **6.** Merck KGaA. European Commission Grants Approval of OGSIVEO for the Treatment of Adults with Desmoid Tumors. EMD Group News Release. August 18, 2025. Accessed September 1, 2026. **7.** Medicines and Healthcare products Regulatory Agency. Nirogacestat hydrobromide approved to treat desmoid tumours. GOV.UK. January 7, 2026. Accessed September 1, 2026. **8.** Swissmedic. *Swiss Public Assessment Report: Ogsiveo (nirogacestat).* Swiss Agency for Therapeutic Products; July 14, 2026. Accessed September 1, 2026. **9.** Emirates Drug Establishment. *Registered Medical Product Directory: Ogsiveo 150 mg.* Government of the United Arab Emirates; June 8, 2026. Accessed September 1, 2026.

OGSIVEO has not been registered, licensed, or approved by the Ministry of Food and Drug Safety (MFDS) in Korea. There is no guarantee or assurance that OGSIVEO will receive registration or regulatory approval from the MFDS or any other regulatory authority. Regulatory approval of OGSIVEO is dependent on review by local regulatory authorities and varies country by country.

This presentation and/or these materials are intended strictly for scientific exchange and medical education among healthcare professionals. They do not constitute commercial promotion or marketing, nor do they encourage or recommend any off-label or unapproved use of OGSIVEO. Please check with your local market authorisation label for country-specific status and information. Healthcare professionals must base their clinical decisions solely on officially approved prescribing information applicable in their jurisdiction and on their professional judgment.

Please note this initiative is owned and led by Merck KGaA, Darmstadt, Germany. This event is not organised or sponsored by Merck Korea.

OGSIVEO Product Information may vary by region. Therefore, always consult the local prescribing information or the Summary of Product Characteristics (SmPC) in your country before prescribing any product.

▽ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.

Ogsiveo®▽
(nirogacestat)
150 mg & 100 mg tablets

Document code GL-OGS-00062. Date of approval: September 2026.
All rights reserved. OGSIVEO is a registered trademark.
All other trademarks are the property of their respective owners.

MERCK

2026 BOARD OF DIRECTORS

Robin Jones, MD, President

Maureen O'Sullivan, MD, Vice President

Abha Gupta, MD, Secretary

Chandrajit Raut, MD, Treasurer

Silvia Stacchiotti, MD, Immediate Past President

Ashleigh Guadagnolo, MD (2024-2026)

Sebastian Bauer, MD (2024-2026)

Paul Huang, MD (2024-2026)

Ana Sebio, MD, PhD (2025-2027)

Jason Sicklick, MD, FACS (2025-2027)

Odion Binitie, MD, PhD (2025-2027)

Tom Chen, MD (2025-2027)

Dario Callagaro, MD (2026-2028)

Aisha Miah, MBBS, MRCP, FRCR, PhD (2026-2028)

Liz Connolly, MBCHB (2026-2028)

Priya Chadasama, PhD (2026-2028)

Barbara Rapp, Executive Director





deciphera®

a member of
ONO PHARMA

YOUR PARTNER IN RARE TUMORS

Visit our website to learn more

© 2026 Deciphera Pharmaceuticals, LLC. Trademarks are the property of their respective owners.
DCPH-P03697v1 10/26

2026 ANNUAL MEETING

Coex Convention Center • Seoul, South Korea

November 18 – 21, 2026

SCHEDULE AT A GLANCE

WEDNESDAY, NOVEMBER 18, 2026

7:00 AM – 6:00 PM	**Registration**	*Hall D Foyer, 3F*
9:00 AM – 1:00 PM	**TARPSWG**	*201, 2F*
9:00 AM – 4:00 PM	**Foundational Science of Sarcomas Symposium** Chair: *Torsten O. Nielsen MD, PhD FRCPC*	*202-203, 3F*
9:00 AM – 5:00 PM	**Poster Set-Up**	*Hall D2, 3F*
10:00 AM – 10:30 AM	**Coffee Service**	*ASEM Ballroom Foyer, 2F*
1:00 PM – 2:00 PM	**TARPSWG / Ultra Rare / Symposium Lunch**	*ASEM Ballroom Foyer, 2F*
2:00 PM – 4:00 PM	**Ultra-Rare Sarcoma Meeting**	*201, 2F*
4:00 PM – 6:00 PM	**SARC Meeting**	*Auditorium, 3F*
6:00 PM – 7:00 PM	**CTOS WELCOME RECEPTION**	*Hall D & Hall D Foyer, 3F*
7:00 PM – 8:45 PM	**See Sponsored Events on the CTOS Meeting Website**	





In unresectable or metastatic conventional chondrosarcoma,

CLEAR DIRECTION MATTERS



START THE CHONDROSATION

CHONDROSARCOMA.COM/HCP

Intended for US healthcare professionals only.

INHIBRx

MAT-0004 10/26

© 2026 Inhibrx Biosciences, Inc. All rights reserved.

THURSDAY, NOVEMBER 19, 2026

6:30 AM – 5:30 PM	**Registration**	*Hall D Foyer, 3F*
7:00 AM – 8:00 AM	**CTOS Posters and Coffee**	*Hall D2, 3F*
8:00 AM – 8:30 AM	**CTOS OPENING REMARKS**	*Auditorium, 3F*
8:30 AM – 5:00 PM	**SPAGN Hospitality Lounge**	*Meeting Room 1, 3F*
8:30 AM – 9:30 AM	**SESSION 1: Sarcoma Across Borders: Healthcare Systems, Registries & Research** Chairs: *Joanna Szkandera, MD, MSc* *Ilkyu Han, MD, PhD* Moderators: *Yongsung Kim, MD* *Kathrin Schuster*	*Auditorium, 3F*
9:00 AM – 5:30 PM	**Nursing and Allied Health Meeting**	*209, 2F*
9:30 AM – 10:00 AM	**Coffee Break and Posters**	*Hall D2, 3F*
10:00 AM – 10:30 AM	**Special Presentation**	*Auditorium, 3F*
10:30 AM – 11:30 AM	**SESSION 2: Adaptive Radiotherapy: Precision in a Changing Landscape** Chair: *Aisha B. Miah, MBBS, MRCP, FRCR, PhD* Moderators: *Andrew J. Bishop, MD*	*Auditorium, 3F*

Parabilis MEDICINES

Creating
extraordinary
medicines

Advancing Helicons™: a new class of α-helical peptides targeting historically undruggable proteins for patients with serious diseases

PARABILISMED.COM

GENERAL info@parabilismed.com
MEDIA media@parabilismed.com
PARTNERS partners@parabilismed.com

CELEBRATING

5 YEARS

ON THE U.S. MARKET

Fyarro®

sirolimus protein-bound particles
for injectable suspension (albumin-bound)

Explore 5 years of FYARRO ›

FYARRO® is approved for use in the United States only and has not been approved by regulatory authorities outside the U.S.

FYARRO® is a registered trademark of Aadi Bioscience, Inc. © 2026 Aadi Bioscience, Inc. All rights reserved. US-FYA-2600028 8/26

AADI bioscience

A proud sponsor of CTOS 2026

THURSDAY, NOVEMBER 19, 2026, CONTINUED

11:30 AM – 12:00 PM	**HERMAN SUIT LECTURE** **The Enduring Vision of Herman Suit: From Foundations to Future Frontiers** Lecturer: *Elizabeth H. Baldini, MD*	*Auditorium, 3F*
12:00 PM – 12:45 PM	**CTOS Lunch**	*Hall D1, 3F*
12:45 PM – 2:15 PM	**SESSION 3: Molecular Pathogenetics and Cellular Origins of Sarcoma** Chair: *Josephine K. Dermawan, MD, PhD* Moderators: *Rebecca A. Gladdy, MD, PhD* *Joanna Przybyl, PhD*	*Auditorium, 3F*
2:15 PM – 3:15 PM	**SESSION 4: Emerging Sarcoma Entities and Pathologic Diagnostics** Chair: *Josephine K. Dermawan, MD, PhD* Moderators: *Cristina R. Antonescu, MD* *Jeong Mo Bae, MD, PhD*	*Auditorium, 3F*
3:15 PM – 3:30 PM	**Coffee Break and Posters**	*Hall D2, 3F*
3:30 PM – 4:30 PM	**SESSION 5: Preclinical Models and Translational Strategies in Sarcoma** Chair: *Josephine K. Dermawan, MD, PhD* Moderators: *Priya Chudasama, PhD* *Jason K. Sicklick, MD, FACS*	*Auditorium, 3F*
4:30 PM – 5:30 PM	**SESSION 6: Poster Discussion** Chair & Moderator: *Joanna Szkandera, MD, MSc* Moderator: *Ilkyu Han, MD, PhD*	*Auditorium, 3F*
5:30 PM – 6:30 PM	**POSTER RECEPTION**	*Hall D2, 3F*
6:00 PM – 10:00 PM	**See Sponsored Events on the CTOS Meeting Website**	





FRIDAY, NOVEMBER 20, 2026

6:00 AM – 6:00 PM	**Registration**	*Hall D Foyer, 3F*
7:00 AM – 9:00 AM	**CTOS Posters and Coffee**	*Hall D2, 3F*
7:30 AM – 8:45 AM	**Sunrise Mentorship**	*Hall D1 / D2, 3F*
7:45 AM – 8:45 AM	**CTOS Executive Board Meeting**	*Meeting Room 2, 3F*
8:30 AM – 5:00 PM	**SPAGN Hospitality Lounge**	*Meeting Room 1, 3F*
9:00 AM – 10:30 AM	**SESSION 7: SARCOMA OF THE YEAR: Rhabdomyosarcoma** Chair: *Aisha B. Miah, MBBS, MRCP, FRCR, PhD* Moderators: *Douglas S. Hawkins, MD* *Lu Xie, MD*	*Auditorium, 3F*
10:30 AM – 11:00 AM	**NINA AXELRAD LECTURE** **How We Worn the Road Less Traveled: Lessons and Opportunities in Rare Cancers** Lecturer: *William D. Tap, MD*	*Auditorium, 3F*
11:00 AM – 11:30 AM	**Coffee Break and Posters**	*Hall D2, 3F*
11:30 AM – 1:00 PM	**SESSION 8: Late Breaking Abstracts and Updates- Can They Change Practice?** Chairs: *Aisha B. Miah, MBBS, MRCP, FRCR, PhD* *Joanna Szkandera, MD, MSc* Moderators: *Marco Fiore, MD, FACS, FEBS* *Andrew J. Wagner, MD, PhD*	*Auditorium, 3F*
1:00 PM – 2:00 PM	**CTOS Lunch**	*Hall D1, 3F*
1:00 PM – 2:00 PM	**CTOS Board of Directors Lunch**	*Meeting Room 2, 3F*
1:00 PM – 2:00 PM	**Young Investigators Group Lunch**	*201, 2F*
2:00 PM – 3:15 PM	**SESSION 9: Bone Tumors: Advances in Orthopedic Oncology** Chairs: *Ilkyu Han, MD, PhD* *Michiel A.J. Van de Sande, Dr, PhD* Moderators: *Maria Anna Smolle, PD, MD* *Sandra Strauss, FRCP, PhD*	*Auditorium, 3F*
3:15 PM – 4:00 PM	**SESSION 10: Debate** **To Beam or Not to Beam? Who Really Benefits from Radiotherapy in Soft Tissue Sarcoma?** Chairs: *Ilkyu Han, MD, PhD* *Michiel A.J. Van de Sande, Dr, PhD*	*Auditorium, 3F*
4:00 PM – 4:15 PM	**Coffee Break and Posters**	*Hall D2, 3F*





GSK

Getting ahead of cancer together



©2026 GSK group of companies or its licenses.
All rights reserved.
NP-GBL-AOU-BNNR-260001 July 2026

FRIDAY, NOVEMBER 20, 2026, CONTINUED

4:15 PM – 5:15 PM	**SESSION 11: GIST at a Crossroads: New Strategies in Combination and Sequencing** Chair: *Joanna Szkandera, MD, MSc* Moderators: *Edwin Choy, MD, PhD* *Johanna Falkenhorst, MD*	*Auditorium, 3F*
5:15 PM – 6:00 PM	**Special Entertainment Session**	*Auditorium, 3F*
7:00 PM – 10:00 PM	**CTOS GALA DINNER**	*Grand Ballroom, 1F*
10:00 PM – 1:00 AM	**CTOS Gala After Party**	*Auditorium Foyer, 3F*





Join us at the CTOS Annual Meeting

HEAR FROM AN EXPERT PANEL

The Evolving Landscape in Advanced GIST:

Phase 3 Peak Pivotal Trial in Second-Line Disease and Emerging TKI Combination Strategies in the First-Line Setting

Wednesday, November 18, 2026 | 7:00 PM–8:00 PM KST
Refreshments will be available | Room 203, Second Floor
COEX Convention & Exhibition Center

MODERATOR



William D Tap, MD
Chief, Sarcoma Medical Oncology Service,
Memorial Sloan Kettering Cancer Center



Neeta Somaiah, MD
Department Chair and Professor,
Sarcoma Medical Oncology,
The University of Texas MD Anderson Cancer Center



Andrew J Wagner, MD, PhD
Senior Physician, Sarcoma Center,
Dana-Farber Cancer Institute;
Associate Professor of Medicine,
Harvard Medical School

To register for this session, click HERE

For questions, please contact cogent@pixacore.com

CTOS, Connective Tissue Oncology Society; GIST, gastrointestinal stromal tumor; TKI, tyrosine kinase inhibitor.

Cogent Biosciences is a trademark of Cogent Biosciences, Inc.
© 2026 Cogent Biosciences. M-KR-GIST-0004 11/26

SATURDAY, NOVEMBER 21, 2026

7:30 AM – 5:00 PM	**Registration**	*Hall D Foyer, 3F*
8:00 AM – 9:00 AM	**CTOS Posters and Coffee**	*Hall D2, 3F*
8:30 AM – 5:00 PM	**SPAGN Hospitality Lounge**	*Meeting Room 1, 3F*
9:00 AM – 10:00 AM	**SESSION 12: The Intermediate Spectrum: TGCT, Fibromatosis & Beyond** Chair: *Michiel A.J. Van de Sande, Dr, PhD* Moderators: *June Hyuk Kim, MD* *Hans Gelderblom, MD, PhD*	*Auditorium, 3F*
10:00 AM – 11:00 AM	**SESSION 13: Multidisciplinary Frontiers: Retroperitoneal & Abdomino-Pelvic Sarcomas** Chair: *Joanna Szkandera, MD, MSc* Moderators: *Markus Albertsmeier, MD* *Dirk Strauss, FCS, FRCS*	*Auditorium, 3F*
11:00 AM – 11:15 AM	**Coffee Break and Posters**	*Hall D2, 3F*
11:15 AM – 12:15 PM	**SESSION 14: Emerging Therapies in Sarcoma: From Novel Targets to Immunotherapy** Chairs: *Joanna Szkandera, MD, MSc* *Josephine K. Dermawan, MD, PhD* Moderators: *Attila Kollár, MD* *Roberta Sanfilippo, MD*	*Auditorium, 3F*
12:15 PM – 1:15 PM	**SESSION 15: How Does Age Influence Sarcoma Management?** Chair: *Michiel A.J. Van de Sande, Dr, PhD* Moderators: *Matilda Lee, MBBS* *Winan J. van Houdt, Dr.*	*Auditorium, 3F*
1:15 PM – 2:15 PM	**CTOS Lunch**	*Hall D1, 3F*
1:15 PM – 2:15 PM	**CTOS All Committees Meeting Lunch**	*201, 2F*
2:15 PM – 3:15 PM	**SESSION 16: Patient-Centered Care & Survivorship: Living with and Beyond Sarcoma** Chair: *Aisha B. Miah, MBBS, MRCP, FRCR, PhD* Moderators: *Bernd Kasper, MD, PhD* *Stine Naess, RN*	*Auditorium, 3F*
3:15 PM – 4:15 PM	**SESSION 17: Site-Specific Strategies: Multidisciplinary Management of Head & Neck, Thoracic, Trunk & Extremity Sarcomas** Chairs: *Ilkyu Han, MD, PhD* *Michiel A.J. Van de Sande, Dr, PhD* Moderators: *Keisuke Ae, PhD* *Kilian E. Salerno, MD*	*Auditorium, 3F*
4:15 PM – 4:30 PM	**Coffee Break and Posters**	*Hall D2, 3F*
4:30 PM – 5:30 PM	**SESSION 18: From Data to Decisions: AI Across the Sarcoma Care Pathway** Chair: *Michiel A.J. Van de Sande, Dr, PhD* Moderators: *Fahima Dossa, MD, PhD* *Shintaro Iwata, MD, PhD*	*Auditorium, 3F*
5:30 PM – 6:00 PM	**CTOS Business Meeting**	*Auditorium, 3F*
6:00 PM	**Adjourn**	

See You Next Year in Vienna, Austria – October 27-30, 2027!

Our member groups



Join the network
sarcoma-patients.org

Sarcoma Patient Advocacy Global Network

ctos®

Bringing together the world's sarcoma specialists.







Annual Meeting

Vienna Austria

October 27-30, 2027

ctos®

Bringing together the world's sarcoma specialists®

The Connective Tissue Oncology Society

For more information,
Please visit the CTOS website:
www.ctos.org

P.O. Box 320574 Alexandria, VA 22320
Phone: 301/502-7371 e-mail: ctos@ctos.org

Barbara Rapp, Executive Director